Today’s guest post comes from Steve Randall, Chief Technology Architect at ConnectiveRx.
Steve examines how artificial intelligence (AI) is reshaping the role of patient support hubs in the specialty drug ecosystem. As policy, payer, and gross-to-net pressures mount, he argues that the hub model must evolve from a service function into a revenue-protection strategy—one that uses “embedded AI” to enhance, not replace, human judgment.
To learn more, download ConnectiveRx’s free eBook: 8 Questions Patient Access Leaders Should Ask About AI—But Aren’t.
Read on for Steve’s insights.
Drug Channels delivers timely analysis and provocative opinions from Adam J. Fein, Ph.D., the country's foremost expert on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of more than 100,000 subscribers and followers. Learn more...
